Paid Clinical Trials for Blood Disorders, Abetalipoproteinemia

Paid Clinical Trials and Focus Groups by Category

All Categories ... by Medical Condition » ... Blood Disorders » ... Abetalipoproteinemia

A Clinical Trial of OXi4503 for Relapsed and Refractory Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Conditions: Leukemia, Myelogenous, Acute; Myelodysplastic Syndromes
Intervention: Drug: Oxi4503
Sponsor: University of Florida
Not yet recruiting - verified March 2010
A Phase 2 Study of AZD6244 in Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: AZD6244 hydrogen sulfate capsules
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified March 2010
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease

Condition: Sickle Cell Disease
Intervention: Drug: Lexiscan
Sponsors: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Children's Hospital Boston; Washington University School of Medicine; LaJolla Institute for Allergy and Immunology; National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified March 2010
Azacitidine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With T(15;17)(q22;q12); Adult Acute Myeloid Leukemia With T(16;16)(p13;q22); Adult Acute Myeloid Leukemia With T(8;21)(q22;q22); Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Drug: gemtuzumab ozogamicin
Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting - verified March 2010
Multicenter Transplant Study for FA

Condition: Fanconi Anemia
Interventions: Drug: Chemotherapy Preparative Regimen; Biological: Miltenyi CliniMACS
Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting - verified March 2010
Connect™ MM- The Multiple Myeloma Disease Registry

Condition: Multiple Myeloma
Intervention:
Sponsor: Celgene Corporation
Recruiting - verified March 2010
Lenalidomide and High-Dose Melphalan

Conditions: Myeloma; Stem Cell Transplantation
Interventions: Drug: Lenalidomide; Drug: Melphalan
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: pomalidomide; Drug: dexamethasone; Drug: rituximab
Sponsors: Dana-Farber Cancer Institute; Celgene Corporation
Not yet recruiting - verified March 2010
Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant

Conditions: Cancer Survivor; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Testicular Germ Cell Tumor
Interventions: Genetic: DNA analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2010
Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD)

Condition: Sickle Cell Disease
Interventions: Drug: Propranolol; Drug: Placebo
Sponsors: Duke University; National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified February 2010
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With T(15;17)(q22;q12); Adult Acute Myeloid Leukemia With T(16;16)(p13;q22); Adult Acute Myeloid Leukemia With T(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia; Blastic Phase Chronic Myelogenous Leukemia; Chronic Phase Chronic Myelogenous Leukemia; De Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Myelodysplastic/Myeloproliferative Disease, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: plerixafor; Biological: filgrastim; Procedure: peripheral blood stem cell transplantation; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting - verified February 2010
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Peripheral T-Cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Splenic Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: everolimus; Drug: lenalidomide; Other: laboratory biomarker analysis; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Genetic: microarray analysis; Genetic: fluorescence in situ hybridization
Sponsor: Mayo Clinic
Not yet recruiting - verified February 2010
Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma

Conditions: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: plerixafor; Biological: filgrastim; Drug: cyclophosphamide; Procedure: autologous hematopoietic stem cell transplantation; Other: laboratory biomarker analysis
Sponsor: City of Hope Medical Center
Not yet recruiting - verified February 2010
Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha

Condition: Chronic Myeloid Leukemia
Intervention: Other: Discontinuation of therapy
Sponsor: University of Michigan Cancer Center
Recruiting - verified February 2010
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome

Conditions: Acute Lymphocytic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome; Chronic Myelogenous Leukemia
Interventions: Drug: bortezomib; Drug: belinostat; Other: laboratory biomarker analysis; Genetic: western blotting; Other: pharmacological study; Other: flow cytometry
Sponsors: Virginia Commonwealth University; National Cancer Institute (NCI)
Not yet recruiting - verified February 2010
Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect

Condition: Purpura, Thrombocytopenic, Idiopathic
Interventions: Drug: Eltrombopag; Drug: Eltrombopag
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
A Pediatric Study of a Plerixafor Containing Regimen In Second Allogenic Stem Cell Transplantation

Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Myelodysplastic Syndrome; Non-Hodgkin's Lymphoma
Intervention: Drug: Plerixafor
Sponsor: St. Jude Children's Research Hospital
Not yet recruiting - verified March 2010
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: KW-2478 and bortezomib
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin UK, Ltd.; Kyowa Hakko Kirin Company, Limited
Not yet recruiting - verified January 2010
Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System

Conditions: Chronic Granulomatous Disease (CGD); Atherosclerosis; Immune Deficiencies; Inflammatory Bowel Disease
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2009
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Condition: Myelodysplastic Syndrome
Interventions: Drug: Ezatiostat Hydrochloride; Drug: Lenalidomide (Revlimid®)
Sponsor: Telik
Recruiting - verified February 2010
A Phase 1 Study of Brentuximab Vedotin Combined With ABVD for Hodgkin Lymphoma

Condition: Disease, Hodgkin
Interventions: Drug: brentuximab vedotin; Drug: doxorubicin; Drug: vinblastine; Drug: dacarbazine; Drug: bleomycin
Sponsors: Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study

Condition: Multiple Myeloma
Interventions: Drug: lenalidomide; Drug: melphalan
Sponsors: Weill Medical College of Cornell University; Celgene Corporation
Recruiting - verified March 2010
Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive

Condition: Severe Hemophilia A
Interventions: Drug: FVIII Concentrates; Drug: FVIII/VWF concentrates
Sponsors: City of Hope Medical Center; Grifols Biologicals Inc.; CSL Behring; Talecris Biotherapeutics; Biotest Pharmaceuticals Corporation
Recruiting - verified March 2010
An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Renal Anemia

Condition: Anemia
Intervention:
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified March 2010
Ferumoxytol Compared to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease

Conditions: Iron Deficiency; Anemia; Kidney Disease
Interventions: Drug: ferumoxytol; Drug: iron sucrose
Sponsor: AMAG Pharmaceuticals, Inc.
Recruiting - verified February 2010
Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Condition: Refractory Multiple Myeloma
Interventions: Drug: bendamustine hydrochloride; Drug: lenalidomide; Drug: dexamethasone
Sponsor: Mayo Clinic
Recruiting - verified March 2010
Peripheral Blood Stem Cell Transplantation Using the CliniMACS Device

Conditions: Malignant Diseases; Non-malignant Diseases
Interventions: Device: CliniMACS (CD+3 depletion); Device: CliniMACS (CD 34+ positive selection)
Sponsors: Medical College of Wisconsin; Children's Hospital of Philadelphia
Recruiting - verified February 2010
Blood Pressure Effects of Nebivolol Versus Lisinopril in New Onset or Worsening Hypertension Induced by Bevacizumab

Condition: Hypertension
Interventions: Drug: Nebivolol; Drug: Lisinopril
Sponsor: University of Mississippi Medical Center
Recruiting - verified February 2010
Lymph Fluid and Blood Collection for Identification of Novel Biomarkers

Condition: Adenocarcinoma of the Breast
Intervention:
Sponsor: Indiana University
Not yet recruiting - verified February 2010
Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients

Conditions: Pre-Hypertension; Hypertension
Interventions: Drug: Potassium, Magnesium, Citrate; Drug: Potassium Chloride
Sponsor: University of Texas Southwestern Medical Center
Recruiting - verified April 2009
Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension

Conditions: Pulmonary Hypertension; Sickle Cell Disease; Thalassemia
Interventions: Drug: L-Glutamine; Drug: L-Glutamine
Sponsor: Children's Hospital & Research Center Oakland
Recruiting - verified February 2010
Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children

Condition: Cerebral Palsy
Interventions: Biological: Cord Blood Infusion; Biological: Intravenous Sham
Sponsor: Medical College of Georgia
Recruiting - verified February 2010
Modal Day Analysis of Self Monitoring Blood Glucose Versus Continuous Glucose Monitoring

Condition: Type 2 Diabetes
Interventions: Other: SMBG to guide clinical decisions; Other: SMBG and CGM
Sponsors: Park Nicollet Institute; International Diabetes Center at Park Nicollet; Abbott Diabetes Care
Recruiting - verified February 2010
Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Conditions: Graft Versus Host Disease; Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Blastic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; De Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Relapsing Chronic Myelogenous Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Waldenstrom Macroglobulinemia
Interventions: Drug: rituximab; Drug: mycophenolate mofetil; Drug: tacrolimus; Drug: anti-thymocyte globulin; Procedure: allogeneic hematopoietic stem cell transplantation; Other: laboratory biomarker analysis; Biological: graft versus host disease prophylaxis/therapy; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: busulfan; Radiation: total-body irradiation; Biological: graft-versus-tumor induction therapy; Biological: immunosuppressive therapy
Sponsor: University of Nebraska
Recruiting - verified March 2010
Practice-based Trial of Blood Pressure Control in African Americans

Conditions: Hypertension; Physical Activity; Diet; Medication Adherence
Interventions: Behavioral: Therapeutic Lifestyle Changes (MINT-TLC); Behavioral: Usual Care
Sponsors: New York University School of Medicine; Columbia University; Hebrew Home for the Aged; New York City Health and Hospitals Corporation
Not yet recruiting - verified February 2010
Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia

Condition: Chronic Lymphocytic Leukemia
Intervention: Other: No Intervention
Sponsor: Dartmouth-Hitchcock Medical Center
Not yet recruiting - verified February 2010
Azilsartan Medoxomil Study in Hypertensive Children

Condition: Hypertension
Interventions: Drug: Azilsartan medoxomil (TAK-491); Drug: Azilsartan medoxomil (TAK-491); Drug: Azilsartan medoxomil (TAK-491); Drug: Azilsartan medoxomil (TAK-491)
Sponsor: Takeda Global Research & Development Center, Inc.
Not yet recruiting - verified February 2010
A Trial Comparing Viaject Versus Humalog in Pumps: Effect on Postprandial Blood Sugars

Condition: Diabetes Mellitus
Intervention: Drug: VIAject U-100 Insulin
Sponsors: Stanford University; Biodel; Barbara Davis Center for Childhood Diabetes
Not yet recruiting - verified February 2010
Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera

Condition: Polycythemia Vera
Intervention: Drug: Erlotinib
Sponsors: University of Oklahoma; OSI Pharmaceuticals
Recruiting - verified February 2010
A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura

Condition: Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Intervention: Biological: Romiplostim
Sponsor: Amgen
Recruiting - verified February 2010
Trial to Evaluate the Efficacy and Safety of a New Formulation of Kogenate for Hemophilia A

Conditions: Blood Coagulation Disorders; Hemophilia A
Interventions: Biological: Recombinant Factor VIII (Kogenate PF, BAY81-8973); Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222); Biological: Recombinant Factor VIII (Kogenate PF, BAY81-8973); Biological: Recombinant Factor VIII (Kogenate PF, BAY81-8973)
Sponsor: Bayer
Recruiting - verified March 2010
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: carfilzomib, lenalidomide plus dexamethasone; Drug: carfilzomib, lenalidomide plus dexamethasone
Sponsors: University of Michigan Cancer Center; Onyx Therapeutics, Inc.; Celgene Corporation
Recruiting - verified February 2010
Feasibility Study of Anti-inflammatory Cytokines in Whole Blood in Osteoarthritis Patients

Condition: Osteoarthritis
Intervention:
Sponsor: Biomet, Inc.
Not yet recruiting - verified March 2010
Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy

Condition: Multiple Myeloma
Intervention: Drug: CEP-18770
Sponsor: Cephalon
Recruiting - verified March 2010
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

Conditions: Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Interventions: Drug: brentuximab vedotin; Drug: rifampin; Drug: midazolam; Drug: ketoconazole; Drug: brentuximab vedotin
Sponsor: Seattle Genetics, Inc.
Recruiting - verified February 2010
Cardiac Safety Study of Brentuximab Vedotin (SGN-35).

Conditions: Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
Sponsor: Seattle Genetics, Inc.
Recruiting - verified February 2010
To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

Condition: Myelodysplastic Syndromes
Interventions: Drug: decitabine; Drug: azacitidine
Sponsor: Eisai Inc.
Not yet recruiting - verified February 2010
A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: PF-03654746; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: Southern blotting; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Efficacy and Safety of TAK-491 and Chlorthalidone Compared to Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension.

Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

Condition: Multiple Myeloma
Interventions: Drug: Perifosine; Drug: Perifosine Placebo; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Keryx / AOI Pharmaceuticals, Inc.; Dana-Farber Cancer Institute
Recruiting - verified March 2010
THE IMPROVE TRIAL: Improving Pain Management and Outcomes With Various Strategies of Patient-Controlled Analgesia (PCA)

Condition: Sickle Cell Disease
Interventions: Other: High Demand / Low Infusion; Other: PCA Dosing Plan
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
Eltrombopag for Post Transplant Thrombocytopenia

Condition: Thrombocytopenia
Interventions: Drug: Eltrombopag; Drug: Placebo
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified February 2010
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant

Conditions: Multiple Myeloma; Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: plerixafor; Drug: filgrastim
Sponsor: Mayo Clinic
Recruiting - verified March 2010
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Recruiting - verified March 2010
Donor Lymphocytes in Preventing and Treating Cytomegalovirus Infection or Adenovirus Infection in Patients Who Have Undergone Umbilical Cord Blood Transplant

Condition: Cancer
Interventions: Biological: allogeneic CMV/AdV-specific cytotoxic T lymphocytes; Other: laboratory biomarker analysis
Sponsors: Baylor College of Medicine; National Cancer Institute (NCI)
Recruiting - verified December 2009
Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Methemoglobinemia; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonmalignant Neoplasm
Interventions: Drug: chemotherapy; Drug: dapsone; Other: medical chart review; Procedure: assessment of therapy complications
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2009
Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma

Conditions: Advanced Solid Tumors; Multiple Myeloma
Intervention: Biological: ACE-041
Sponsor: Acceleron Pharma, Inc.
Recruiting - verified February 2010
Initial Treatment of Patients With Immune Thrombocytopenic Purpura

Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: Dexamethasone USP Micronized; Drug: Prednisone
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2010
IMGN901 in Combination With Lenalidomide and Dexamethasone

Condition: Multiple Myeloma
Intervention: Drug: IMGN901
Sponsor: ImmunoGen, Inc.
Recruiting - verified March 2010
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390

Conditions: Hepatitis C; Thrombocytopaenia
Intervention: Drug: Eltrombopag
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders

Conditions: Leukemia; Non-Hodgkins Lymphoma; Hodgkins Lymphoma; MDS; Multiple Myeloma
Interventions: Drug: EPOCH-F/R; Drug: FLAG; Drug: Transplant Preparative Regimen (Flu/Cy/Mes); Drug: GVHD Prophylaxis (tacrolimus and sirolimus); Procedure: Double Cord Blood Transplantation
Sponsor: National Cancer Institute (NCI)
Recruiting - verified November 2009
Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B

Condition: Hemophilia B
Intervention: Genetic: Gene Transfer
Sponsors: St. Jude Children's Research Hospital; Stanford University; Katharine Dormandy Haemophilia Centre and Haemostasis Unit
Recruiting - verified March 2010
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725

Condition: Congenital FXIII Deficiency
Intervention: Drug: recombinant factor XIII
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia

Condition: Leukemia
Interventions: Genetic: fluorescence in situ hybridization; Genetic: mutation analysis; Genetic: nucleic acid sequencing; Genetic: polymerase chain reaction; Genetic: western blotting; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2010
Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720

Condition: Leukemia
Intervention: Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

Conditions: Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Lymphocytic Leukemia; Myelodysplasia; Non-Hodgkin's Lymphoma; Hodgkin's Disease; Multiple Myeloma; Myelofibrosis; Anemia, Aplastic; Hemoglobinuria, Paroxysmal
Intervention: Drug: Basiliximab
Sponsor: Indiana University School of Medicine
Recruiting - verified March 2010
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma

Condition: Brain and Central Nervous System Tumors
Interventions: Genetic: fluorescence in situ hybridization; Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Other: immunohistochemistry staining method
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Tissue and Blood Samples From Patients With High-Grade Glioma

Condition: Brain and Central Nervous System Tumors
Interventions: Genetic: DNA ploidy analysis; Genetic: fluorescence in situ hybridization; Genetic: microsatellite instability analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: diagnostic laboratory biomarker analysis; Other: flow cytometry; Other: immunohistochemistry staining method
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma

Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis

Conditions: Anemia; Chronic Kidney Disease
Interventions: Drug: MK2578; Drug: Comparator: MK2578; Drug: Comparator: MK2578; Drug: Comparator: darbepoetin alfa
Sponsor: Merck
Recruiting - verified March 2010
Safety and Tolerability of TAK-491 Plus Chlorthalidone Compared to Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Essential Hypertension

Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: Olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonmalignant Neoplasm
Interventions: Biological: trivalent influenza vaccine; Other: immunoenzyme technique; Other: laboratory biomarker analysis
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified August 2009
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Conditions: Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: everolimus; Drug: panobinostat; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified August 2009
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

Conditions: Venous Thromboembolism; Deep Vein Thrombosis; Pulmonary Embolism; Thromboembolism; Venous Thrombosis
Interventions: Drug: edoxaban tosylate(DU-176b); Drug: low molecular weight heparin/unfractionated heparin; Drug: warfarin
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified February 2010
Study of Blood Samples From Newborns With Down Syndrome

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma

Conditions: Lymphoma; Nonneoplastic Condition
Interventions: Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
An Open-Label, Single-Arm Pilot Study of the Efficacy of Erythropoietin Alfa in Improving Peak Oxygen Consumption in Elderly Subjects With Unexplained Anemia

Condition: Anemia
Intervention: Drug: Epoetin alfa
Sponsors: Stanford University; National Institute on Aging (NIA)
Recruiting - verified February 2010
A Study Of PF-04449913 In Select Hematologic Malignancies Or With Dasatinib In Chronic Myeloid Leukemia (CML)

Condition: Hematologic Malignancies
Interventions: Drug: PF-04449913; Drug: dasatinib
Sponsor: Pfizer
Recruiting - verified March 2010
Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonmalignant Neoplasm; Viral Infection
Interventions: Other: cytology specimen collection procedure; Other: fluorescent antibody technique; Procedure: assessment of therapy complications
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified August 2009
Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors

Condition: Haemophilia A or B With Inhibitors
Interventions: Drug: activated recombinant human factor VII, long acting; Drug: activated recombinant human factor VII, long acting; Drug: activated recombinant human factor VII, long acting
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Home Visits or Standard Therapy in Treating Patients Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Psychosocial Effects of Cancer and Its Treatment; Therapy-related Toxicity
Interventions: Behavioral: exercise intervention; Behavioral: telephone-based intervention; Dietary Supplement: dietary intervention; Other: educational intervention; Other: questionnaire administration; Procedure: allogeneic bone marrow transplantation; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: assessment of therapy complications; Procedure: peripheral blood stem cell transplantation; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment; Procedure: standard follow-up care
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified July 2009
Preventing Acute Chest Syndrome by Transfusion Feasibility Study

Conditions: Sickle Cell Disease; Secretory Phospholipase A2; sPLA2
Interventions: Biological: Single blood transfusion; Behavioral: Standard care
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Condition: Leukemia
Interventions: Drug: Vorinostat; Drug: Azacitidine
Sponsors: M.D. Anderson Cancer Center; Merck
Recruiting - verified March 2010
Infusion of Expanded Cord Blood T Cells

Conditions: Stem Cell Transplantation; Leukemia; Lymphoma; Pediatrics
Interventions: Radiation: Total Body Irradiation (TBI); Drug: Melphalan; Drug: Thiotepa; Drug: Fludarabine; Drug: Rituximab; Drug: Etoposide; Drug: Anti-thymocyte globulin (ATG); Drug: Mycophenolate Mofetil (MMF); Drug: Tacrolimus; Procedure: Cord Blood Infusion; Drug: G-CSF; Procedure: Ex vivo expanded T cell Infusion
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Dapagliflozin; Drug: Placebo; Drug: Hydrochlorothiazide
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified December 2009
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

Condition: Factor XIII Deficiency
Intervention: Biological: FXIII Concentrate Human
Sponsor: CSL Behring
Recruiting - verified March 2010
An SGN-35 Trial for Patients Who Have Previously Participated in an SGN-35 Study

Conditions: Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-35
Sponsor: Seattle Genetics, Inc.
Recruiting - verified February 2010
Effect of Cinnamon Extract on Insulin Resistance in Polycystic Ovary Syndrome

Conditions: Polycystic Ovary Syndrome; Insulin Resistance
Interventions: Dietary Supplement: Cinnamon Supplementation; Dietary Supplement: Placebo (wheat flour)
Sponsor: Pennington Biomedical Research Center
Recruiting - verified March 2010
Effect of Red Blood Cell Transfusion on Brain Metabolism in Patients With Subarachnoid Hemorrhage

Conditions: Subarachnoid Hemorrhage; Vasospasm
Intervention: Biological: Red blood cell transfusion
Sponsors: Washington University School of Medicine; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2010
Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma

Conditions: Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition
Interventions: Dietary Supplement: defined green tea catechin extract; Genetic: gene expression analysis; Genetic: protein analysis; Other: laboratory biomarker analysis
Sponsors: Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified February 2010
Clopidogrel and Aspirin for the Treatment of Polycythemia Vera

Condition: Polycythemia Vera
Interventions: Drug: Clopidogrel (Plavix); Drug: Placebo; Drug: Aspirin
Sponsor: Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010
Development, Validation and Evaluation of an Adult and Pediatric Eosinophilic Esophagitis Activity Index

Conditions: Deglutition Disorders; Esophageal Diseases; Eosinophilia
Intervention: Other: assessment of disease activity using the EEsAI
Sponsors: University Hospital Inselspital, Berne; Institute of Social and Preventive Medicine, University Bern; Dept. of Gastroenterology, Kantonsspital Olten, Olten; Institute for Pathology, Kantonsspital Lucerne, Lucerne; Mayo Clinic Rochester, Minnesota, USA; University of Cincinnati; University of Colorado, Denver; Northwestern University of Chicago, Illinois, USA; Indiana University School of Medicine; Philadelphia University
Not yet recruiting - verified March 2010
Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells; Genetic: gene expression analysis; Genetic: protein expression analysis; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: immunohistochemistry staining method; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified February 2010
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Other: 3'-deoxy-3'-[18F]fluorothymidine
Sponsors: Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified September 2009
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis

Conditions: Primary Myelofibrosis; Post-Polycythemia Vera; Post-Essential Thrombocytopenia
Interventions: Drug: Panobinostat; Drug: Panobinostat
Sponsor: Novartis
Recruiting - verified March 2010
A Pharmacokinetic Study of Melphalan HCL for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation

Condition: Multiple Myeloma
Interventions: Drug: Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection; Drug: Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)
Sponsor: CyDex Pharmaceuticals, Inc.
Recruiting - verified February 2010
Submission of Stem Cell Transplant Data to CIBMTR and NMDP

Conditions: Autologous Stem Cell Transplantation; Allogeneic Stem Cell Transplantation; Solid Tumors; Blood Cancers
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting - verified November 2009
Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Blood and Bone Marrow Samples From Patients With Myeloma, Waldenstrom's Macroglobulinemia, Amyloidosis, or Monoclonal Gammopathy of Undetermined Significance

Conditions: Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: bendamustine as combination therapy with bortezomib
Sponsor: Cephalon
Recruiting - verified March 2010
A Study Investigating Treatment Factor X in People With Factor X Deficiency

Condition: Factor X Deficiency
Intervention: Biological: Human Coagulation FACTOR X
Sponsor: Bio Products Laboratory
Recruiting - verified March 2010
Study Evaluating 13vPnC in Children With Sickle Cell Disease

Condition: Pneumococcal Conjugate Vaccine
Intervention: Biological: 13vPnC
Sponsor: Wyeth
Recruiting - verified March 2010
Controlling Blood Sugar Levels in Preventing Infection in Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Conditions: Hyperglycemia; Leukemia
Interventions: Biological: insulin glargine recombinant; Drug: therapeutic insulin
Sponsors: Cancer Institute of New Jersey; National Cancer Institute (NCI)
Recruiting - verified July 2009
Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Bendamustine; Drug: Melphalan; Drug: Bendamustine; Drug: Bendamustine; Drug: Bendamustine; Drug: Bendamustine
Sponsor: Weill Medical College of Cornell University
Recruiting - verified March 2010
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

Conditions: Graft Versus Host Disease; Leukemia; Myelodysplastic Syndromes
Interventions: Drug: Fludarabine Phosphate; Drug: Tacrolimus; Drug: Thiotepa; Radiation: Total-Body Irradiation (TBI); Device: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)
Sponsors: Yale University; National Cancer Institute (NCI); Fred Hutchinson Cancer Research Center
Recruiting - verified March 2010
Busulfan in Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: Busulfan
Sponsors: University of Utah; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified February 2010
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma

Conditions: Hematopoietic/Lymphoid Cancer; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; B-cell Adult Acute Lymphoblastic Leukemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Primary Central Nervous System Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Multiple Myeloma; Splenic Marginal Zone Lymphoma; T-cell Adult Acute Lymphoblastic Leukemia; Waldenstrom Macroglobulinemia
Interventions: Drug: panobinostat; Drug: everolimus; Other: laboratory biomarker analysis; Other: pharmacological study; Other: flow cytometry; Other: immunohistochemistry staining method; Other: western blotting
Sponsor: Mayo Clinic
Recruiting - verified March 2010
A Study of the Safety and Effectiveness of CNTO 328 When Added to Velcade-Melphalan-Prednisone in Patients With Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: 328 plus VMP (Part 1, Part 2-Arm A); Drug: VMP Alone (Part 2-Arm B)
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)

Conditions: Leukemia; Pediatrics
Interventions: Drug: Epratuzumab; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Mesna; Procedure: Infusion of NK cells; Drug: Interleukin-2
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; University of Chicago; Dana-Farber Cancer Institute; Georgetown University; Johns Hopkins University; M.D. Anderson Cancer Center; University of Alabama at Birmingham; University of California, San Francisco; University of North Carolina; Duke University; Vanderbilt-Ingram Cancer Center; The Indiana University Simon Cancer Center; Mayo Clinic; University of Pittsburgh; University of Michigan Health System
Recruiting - verified March 2010
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer

Condition: Chemotherapy Induced Anemia
Interventions: Biological: Biological: ACE-011; Drug: Placebo
Sponsors: Acceleron Pharma, Inc.; Celgene Corporation
Recruiting - verified March 2010
Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic ITP

Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: eltrombopag; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Prospective, Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP)

Conditions: Thrombocytopenia; Idiopathic Thrombocytopenic Purpura
Intervention: Biological: romiplostim
Sponsor: Amgen
Recruiting - verified March 2010
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Conditions: Cancer; Colon Cancer; Colorectal Cancer; Fever; Locally Advanced; Metastatic Colorectal Cancer; Neutropenia; Rectal Cancer
Interventions: Drug: Pegfilgrastim; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
A Phase 1 Dose-escalation Study of a Cell Cycle Inhibitor With and Without Cytarabine in Patients With Acute Leukemias (Study P05247)

Conditions: Myelogenous Leukemia, Acute; Leukemia, Lymphocytic, Acute; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive; Myelogenous Leukemia, Chronic, Aggressive Phase
Interventions: Drug: SCH 900776; Drug: Cytarabine
Sponsor: Schering-Plough
Recruiting - verified March 2010
Hematopoietic Stem Cell Transplant for Fanconi Anemia

Condition: Fanconi Anemia
Intervention: Device: CliniMACs device
Sponsors: Medical College of Wisconsin; Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2010
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

Conditions: Advanced Myelodysplastic Syndrome; Myelodysplastic Syndrome; Secondary Acute Myeloid Leukemia After MDS; Thrombocytopenia
Interventions: Drug: eltrombopag olamine; Other: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma

Conditions: Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition
Interventions: Genetic: cytogenetic analysis; Genetic: microarray analysis; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

Conditions: Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Intervention: Other: biologic sample preservation procedure
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: polymorphism analysis; Genetic: proteomic profiling; Other: flow cytometry; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified October 2008
Collecting and Storing Blood Samples From Patients With Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonmalignant Neoplasm; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: biologic sample preservation procedure
Sponsors: Cancer Institute of New Jersey; National Cancer Institute (NCI)
Recruiting - verified August 2008
Blood Samples From Patients With Cancer Treated on a Clinical Trial to Control Nausea and Vomiting During Donor Stem Cell Transplant

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nausea and Vomiting; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Other: immunoenzyme technique; Other: laboratory biomarker analysis; Other: medical chart review
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Studying Fentanyl in Patients With Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: fentanyl citrate; Other: pharmacological study
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

Condition: Hypertension
Interventions: Drug: Telmisartan 80mg; Drug: Telmisartan80mg/hydrochlorothiazide25mg; Drug: Telmisartan80mg/hydrochlorothiazide25mg; Drug: Telmisartan
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Endocrine Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Metastatic Cancer; Multiple Myeloma; Parathyroid Neoplasms; Renal Cancer; Thyroid Cancer; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-small Cell Lung Cancer
Intervention: Drug: denosumab
Sponsor: Amgen
Recruiting - verified March 2010
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy

Conditions: Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonneoplastic Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sunitinib malate; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study to Evaluate 24 Hour Blood Sugar Control in Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared to Subjects Taking Metformin XR 1500 mg Uptitrated to Metformin XR 2000 mg

Condition: Type 2 Diabetes
Interventions: Drug: Saxagliptin; Drug: Metformin XR; Drug: Placebo matching Metformin 500 mg; Drug: Metformin XR; Drug: Placebo matching Saxagliptin 5 mg
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified February 2010
A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

Condition: Factor XIII Deficiency
Intervention: Biological: FXIII Concentrate Human
Sponsor: CSL Behring
Recruiting - verified March 2010
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

Condition: Advanced Cancer, Various, NOS
Interventions: Drug: BMS-833923; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Bortezomib
Sponsors: Bristol-Myers Squibb; Exelixis
Recruiting - verified December 2009
Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease

Condition: Breast Cancer
Interventions: Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: proteomic profiling; Genetic: reverse transcriptase-polymerase chain reaction; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: liquid chromatography; Other: mass spectrometry; Other: medical chart review; Procedure: quality-of-life assessment
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma

Conditions: Lymphoma; Small Intestine Cancer
Interventions: Procedure: radionuclide imaging; Procedure: single photon emission computed tomography; Radiation: indium In 111-labeled autologous peripheral blood mononuclear cells; Radiation: indium In 111-labeled autologous polymorphonuclear leukocytes
Sponsors: Holden Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2007
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Conditions: Breast Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Musculoskeletal Complications; Pain; Prostate Cancer; Urinary Complications
Intervention: Drug: zoledronic acid
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collection and Storage of Blood and Tissue Samples From Patients Who Are Undergoing Surgery For Lung Cancer

Condition: Lung Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

Conditions: Acute Ischemic Stroke; Stroke; Brain Infarction
Interventions: Drug: Eptifibatide; Drug: rt-PA
Sponsors: University of Cincinnati; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified February 2010
A Phase 2 Open Label Trial of SGN-35 for Systemic Anaplastic Large Cell Lymphoma

Conditions: Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-35
Sponsor: Seattle Genetics, Inc.
Recruiting - verified February 2010
Sitagliptin Umbilical Cord Blood Transplant Study

Conditions: Leukemia, Myeloid, Acute; Acute Lymphoblastic Leukemia; Myelodysplasia; Leukemia, Myelogenous, Chronic; Lymphoma, Non-Hodgkin
Intervention: Drug: Sitagliptin
Sponsor: Indiana University School of Medicine
Recruiting - verified March 2010
Phase I Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel(Registered Trademark)+CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and Mali

Condition: Malaria
Intervention: Drug: BSAM2/Alhydrogel + CPG 7909
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2009
Growth Factor Signature (GFS) Pilot Study

Conditions: Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia; Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia
Intervention: Other: Comparator: Biomarker evaluation
Sponsor: Merck
Recruiting - verified March 2010
Anemia Treatment for Advanced NSCLC Patients Receiving Chemotherapy

Conditions: Non-small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsor: Amgen
Recruiting - verified March 2010
Fludarabine, Melphalan, Total-Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders

Conditions: Chronic Myeloproliferative Disorders; Fanconi Anemia; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonmalignant Neoplasm; Paroxysmal Nocturnal Hemoglobinuria
Interventions: Biological: anti-thymocyte globulin; Biological: graft-versus-tumor induction therapy; Drug: fludarabine phosphate; Drug: melphalan; Procedure: allogeneic hematopoietic stem cell transplantation; Radiation: total-body irradiation
Sponsors: Roswell Park Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2009
A New Prenatal Blood Test for Down Syndrome

Conditions: Down Syndrome; Trisomy 21
Intervention:
Sponsors: Women and Infants Hospital of Rhode Island; Sequenom, Inc.
Recruiting - verified February 2010
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Conditions: Anemia; Leukemia; Myelodysplastic Syndromes
Interventions: Biological: epoetin alfa; Drug: lenalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Efficacy and Safety of N8 in Haemophilia A Subjects

Condition: Haemophilia A
Interventions: Drug: recombinant factor VIII (N8); Procedure: Blood drawn for laboratory testing
Sponsor: Novo Nordisk
Recruiting - verified March 2010
A Study of BMS-863233 in Patients With Hematologic Cancer

Condition: Refractory Hematologic Cancer
Interventions: Drug: Cdc7-inhibitor (BMS-863233); Drug: Cdc7-inhibitor (BMS-863233)
Sponsors: Bristol-Myers Squibb; Exelixis
Recruiting - verified October 2009
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Other: educational intervention; Other: laboratory biomarker analysis; Other: questionnaire administration; Other: survey administration; Procedure: psychosocial assessment and care; Procedure: stress management therapy; Procedure: support group therapy
Sponsors: University of Colorado, Denver; National Cancer Institute (NCI)
Recruiting - verified January 2009
Utilizing Blood Volume Measurements in the Treatment of Heart Failure Patients

Condition: Congestive Heart Failure
Interventions: Other: Ultrafiltration; Other: Ultrafiltration using BVM
Sponsors: Christiana Care Health Services; Daxor Corporation
Recruiting - verified March 2010
A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease

Conditions: Chronic Kidney Disease; Iron-Deficiency Anemia
Interventions: Drug: IV Iron; Drug: Ferrous Sulfate
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2010
A Pharmacokinetics (Blood Levels), Pharmacodynamics (How the Drug Acts on the Body) and Safety Study Dosing of Rabeprazole in New Borns With Gastroesophageal Reflux Disease (GERD).

Condition: Gastroesophageal Reflux
Intervention: Drug: Rabeprazole sodium
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Eisai Inc.
Recruiting - verified February 2010
A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With TMC114r (Ritonavir), and TMC125 (Etravirine) in HIV-1 Infected Pregnant Women

Conditions: HIV; HIV Infections; Pregnancy
Interventions: Drug: TMC114 (darunavir); Drug: TMC125 (etravirine); Drug: TMC114r (ritonavir)
Sponsors: Tibotec, Inc; Tibotec Therapeutics, a Division of Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified March 2010
The Effect of Hypertension Medications on Renal Blood Flow Measurements in Healthy Males

Condition: Hypertension
Interventions: Drug: Aliskiren; Drug: Aliskiren; Drug: Comparator: Losartan; Drug: Comparator: Placebo to Aliskiren; Drug: Comparator: Placebo to Losartan
Sponsor: Merck
Recruiting - verified March 2010
Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients

Condition: Hematological Malignancies
Interventions: Drug: Ibandronate; Drug: Vitamin Supplements
Sponsors: M.D. Anderson Cancer Center; Roche Pharma AG
Recruiting - verified March 2010
Efficacy and Safety of TAK-491 Combined With Chlorthalidone in Subjects With Moderate to Severe Hypertension

Condition: Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: Chlorthalidone; Drug: Chlorthalidone; Drug: TAK-491; Drug: TAK-491; Drug: TAK-491
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: dasatinib; Drug: vorinostat; Genetic: cytogenetic analysis; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Myelodysplastic Syndromes; Nonmalignant Neoplasm
Interventions: Drug: cyclosporine; Drug: mycophenolate mofetil; Drug: pentostatin; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: protein analysis; Other: flow cytometry; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Other: reduced-intensity transplant conditioning procedure; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: University of Nebraska; National Cancer Institute (NCI)
Recruiting - verified July 2009
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU

Condition: Phenylketonuria
Intervention: Drug: sapropterin dihydrochloride
Sponsor: BioMarin Pharmaceutical
Recruiting - verified March 2010
Efficacy and Safety of Azilsartan Plus Chlorthalidone in Subjects With Moderate to Severe Hypertension

Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: Olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and Melanoma

Condition: Health Status Unknown
Interventions: Other: biologic sample preservation procedure; Other: medical chart review; Other: survey administration; Procedure: evaluation of cancer risk factors
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified January 2009
Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Infection; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Therapy-related Toxicity
Interventions: Biological: immunosuppressive therapy; Other: immunological diagnostic method; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

Condition: Waldenstrom's Macroglobulinemia
Intervention: Biological: Ofatumumab
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant

Conditions: Hematologic Malignancies; Graft vs Host Disease
Interventions: Procedure: reduced intensity, matched related donor stem cell transplant; Drug: tacrolimus (standard GVHD prophylaxis); Drug: mycophenolate (standard GVHD prophylaxis); Drug: vorinostat
Sponsor: University of Michigan Cancer Center
Recruiting - verified February 2010
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myelogenous Leukemia; Chronic Lymphocytic Leukemia; Multiple Myeloma; Waldenstrom's Macroglobulinemia; Myelodysplastic Syndrome; Philadelphia Chromosome-negative CML; Myeloid Metaplasia; Myelofibrosis; Advanced Polycythemia; Non-Hodgkins Lymphoma
Intervention: Drug: TAK-901
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Comparison Study of Daily Ultrafiltration and Twice-weekly Hemodialysis

Condition: End-Stage Renal Disease
Intervention: Procedure: Ultrafiltration
Sponsors: Renal Research Institute; Vizio Medical Devices
Recruiting - verified March 2010
Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome

Conditions: Myelodysplastic Syndrome; Aplastic Anemia
Interventions: Drug: Thymoglobulin; Drug: Cyclosporine; Drug: Methylprednisolone; Drug: G-CSF
Sponsors: M.D. Anderson Cancer Center; Genzyme
Recruiting - verified March 2010
Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: fludarabine phosphate; Drug: melphalan; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Radiation: intensity-modulated radiation therapy; Radiation: tomotherapy; Radiation: total marrow irradiation; Radiation: total nodal irradiation
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Natural Killer Cells and Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: natural killer cell therapy; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: allogeneic bone marrow transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Radiation: total-body irradiation
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified August 2009
Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A

Conditions: Hematologic Disease; Blood Coagulation Disorders
Interventions: Behavioral: Recombinant Factor VIII (Kogenate, BAY 14-2222); Behavioral: Recombinant Factor VIII (Kogenate, BAY 14-2222); Behavioral: Recombinant Factor VIII (Kogenate, BAY 14-2222)
Sponsor: Bayer
Recruiting - verified March 2010
Early Administration of Antithymocyte Globulin Followed By Cyclophosphamide, Busulfan, and Fludarabine Before a Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Kidney Cancer

Conditions: Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: anti-thymocyte globulin; Drug: busulfan; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: methotrexate; Drug: tacrolimus; Genetic: polymerase chain reaction; Other: pharmacological study; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsor: Blood and Marrow Transplant Group of Georgia
Recruiting - verified June 2009
A Phase 4, 6-Week, Randomized Double-Blind, Multicenter, Active-Controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects

Condition: Arthritis, Juvenile Rheumatoid
Interventions: Drug: Celecoxib; Drug: Naproxen
Sponsor: Pfizer
Recruiting - verified March 2010
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Psychosocial Effects of Cancer and Its Treatment; Sarcoma
Interventions: Other: educational intervention; Other: informational intervention; Other: internet-based intervention; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Other: survey administration; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment; Procedure: standard follow-up care
Sponsors: Tufts Medical Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer

Conditions: Leukemia; Lymphoma; Myelodysplastic Syndromes
Interventions: Drug: busulfan; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsor: Northside Hospital, Inc.
Recruiting - verified March 2010
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib

Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: Dasatinib
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: BIW-8962
Sponsor: Kyowa Hakko Kirin Pharma, Inc.
Recruiting - verified January 2009
Interleukin-2 Treatment for Wiskott-Aldrich Syndrome

Conditions: Wiskott-Aldrich Syndrome (WAS); X-linked Thrombocytopenia
Intervention: Drug: Interleukin-2
Sponsors: Children's Hospital of Philadelphia; Novartis
Recruiting - verified March 2010
Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone; Drug: lenalidomide; Other: flow cytometry; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Other: staining method; Procedure: bone marrow aspiration
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified February 2010
Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers

Conditions: Chronic Myeloproliferative Disorders; Depression; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Psychosocial Effects of Cancer and Its Treatment; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: medical chart review; Other: questionnaire administration; Procedure: psychosocial assessment and care
Sponsors: Cancer Institute of New Jersey; National Cancer Institute (NCI)
Recruiting - verified August 2008
Trial Of Double Umbilical Cord Blood Transplantation

Condition: Hematological Malignancies
Interventions: Procedure: full intensity, double umbilical cord, stem cell transplant; Drug: Flu/Bu4 conditioning regimen; Radiation: Total Lymphoid Irradiation (TLI); Drug: Graft versus Host Disease prevention (GVHD prophylaxis)
Sponsor: University of Michigan Cancer Center
Recruiting - verified February 2010
Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes; Lymphoma; Multiple Myeloma; Leukemia, Myelomonocytic, Chronic
Intervention: Drug: azacitidine
Sponsor: Celgene Corporation
Recruiting - verified March 2010
Transfusing Neonates Based on Platelet Mass

Condition: Thrombocytopenia
Intervention:
Sponsors: Christiana Care Health Services; Alfred I. duPont Hospital for Children; Thomas Jefferson University; Abington Memorial Hospital
Recruiting - verified March 2010
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: cyclosporine ophthalmic emulsion; Other: placebo
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Other: educational intervention
Sponsors: Fox Chase Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions

Condition: Myelodysplastic Syndrome (MDS)
Intervention: Other: T2* Cardiac and Liver MRI
Sponsors: Weill Medical College of Cornell University; Novartis Pharmaceuticals
Recruiting - verified March 2010
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis

Conditions: Myelofibrosis; Myeloproliferative Disorders; Polycythemia Vera; Essential Thrombocythemia
Intervention: Drug: SB1518
Sponsor: S*BIO
Recruiting - verified March 2010
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Conditions: Deep Vein Thrombosis; Venous Thrombosis; Postphlebitic Syndrome; Venous Thromboembolism; Post Thrombotic Syndrome
Intervention: Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors: Washington University School of Medicine; McMaster University; Ontario Clinical Oncology Group (OCOG); National Heart, Lung, and Blood Institute (NHLBI); Bacchus Vascular; BSN Medical Inc; Genentech; MEDRAD Interventional/Possis; Mid America Heart Institute; Society of Interventional Radiology Foundation; VasCore at Massachusetts General Hospital
Recruiting - verified February 2010
A Phase I Dose Escalation Study of Oral SB939

Conditions: Solid Tumors; Hematologic Malignancies
Intervention: Drug: SB939
Sponsor: S*BIO
Recruiting - verified March 2010
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: survey administration; Procedure: assessment of therapy complications; Procedure: long-term screening; Procedure: study of high risk factors
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Pain; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: methadone hydrochloride; Drug: morphine sulfate; Drug: oxycodone hydrochloride
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified June 2009
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma (Study P05538AM3)

Conditions: Neoplasms; Lymphoma; Multiple Myeloma
Interventions: Drug: SCH 900105; Drug: SCH 900105; Drug: SCH 900105; Drug: Erlotinib
Sponsors: Schering-Plough; AVEO Pharmaceuticals, Inc.
Recruiting - verified February 2010
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies

Conditions: Acute Myelogenous Leukemia; Chronic Myelogenous Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes; Myelofibrosis
Intervention: Drug: SB1518
Sponsor: S*BIO
Recruiting - verified March 2010
The Effect of Atrial Fibrillation Hemodynamics on Regulation of Cerebral Blood Flow

Condition: Atrial Fibrillation
Intervention: Procedure: non-invasive testing
Sponsor: University of Texas Southwestern Medical Center
Recruiting - verified September 2008
American Ginseng in Treating Patients With Fatigue Caused by Cancer

Conditions: Chronic Myeloproliferative Disorders; Fatigue; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Dietary Supplement: American ginseng; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Oral Nifedipine to Treat Iron Overload

Conditions: Thalassemia; Iron Overload; Hemochromatosis
Interventions: Drug: Nifedipine; Procedure: Phlebotomy; Procedure: Urinalysis; Procedure: Echocardiogram; Procedure: Electrocardiogram
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2009
Evaluate the Side Effects and Benefits of Rosiglitazone With or Without Diet and Exercise in Type II Diabetes Mellitus

Condition: Type II Diabetes Mellitus
Intervention: Other: Rosiglitazone with diet and exercise
Sponsors: American Scitech International; Proactive Clinical Research; GlaxoSmithKline
Not yet recruiting - verified March 2010
Doppler Ultrasound Probe for Blood Flow Detection in Severe Upper Gastrointestinal Hemorrhage

Conditions: UGI Bleeding; Ulcer Hemorrhage; Stigmata of Recent Hemorrhage; Endoscopy; Randomized Controlled Trials
Intervention: Device: Doppler ultrasound probe for blood flow detection
Sponsor: Department of Veterans Affairs
Recruiting - verified February 2010
A Phase III Study of Alpharadin (Radium-223)in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

Conditions: Hormone Refractory Prostate Cancer; Bone Metastases
Interventions: Drug: Alpharadin (Radium-223); Drug: Placebo
Sponsor: Algeta ASA
Recruiting - verified March 2009
Study of MLN8237 in Patients With Advanced Hematological Malignancies

Conditions: B-cell Follicular Lymphoma; B-cell Marginal Zone Lymphoma; Diffuse Large B-cell Lymphoma; B-cell Mantle Cell Lymphoma; B-cell Small Lymphocytic Lymphoma (SLL); B-Cell Chronic Lymphocytic Leukemia (B-CLL); Multiple Myeloma; Waldenstrom's Macroglobulinemia
Intervention: Drug: MLN8237
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: rituximab; Drug: busulfan; Drug: carmustine; Drug: cyclophosphamide; Drug: cytarabine; Drug: etoposide; Drug: fludarabine phosphate; Drug: melphalan; Radiation: total-body irradiation
Sponsors: Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified January 2010
Correlation of MR Thermal Imaging to Actual Size of Ablation During Laser Ablation Therapy

Conditions: Advanced Cancer; Bone Metastases
Interventions: Procedure: Laser Ablation; Procedure: Magnetic Resonance Thermal Imaging
Sponsors: M.D. Anderson Cancer Center; BioTex, Inc.
Recruiting - verified March 2010
Monoclonal Antibody IMC-A12 and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer

Conditions: Adrenocortical Carcinoma; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Sarcoma; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: cixutumumab; Drug: temsirolimus
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2010
A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced of Refractory Leukemia or Myelodysplastic Syndrome.

Conditions: Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelodysplastic Syndromes; Leukemia, Lymphocytic, Chronic, B-Cell
Intervention: Drug: JNJ-26481585.
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Pain; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: questionnaire administration; Procedure: acupressure therapy; Procedure: biopsy; Procedure: bone marrow aspiration; Procedure: pain therapy
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
CEP-701 (Lestaurtinib) in Myelofibrosis

Conditions: Myelofibrosis; Essential Thrombocythemia; Polycythemia Vera
Intervention: Drug: CEP-701 (Lestaurtinib)
Sponsor: Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010
Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis

Condition: Myelofibrosis
Intervention: Drug: bevacizumab (Avastin)
Sponsor: Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Pain; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: educational intervention; Other: medical chart review; Other: questionnaire administration; Procedure: pain therapy; Procedure: quality-of-life assessment
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified October 2009
Research Tissue Bank

Conditions: Myelofibrosis; Idiopathic Myelofibrosis; Essential Thrombocythemia; Polycythemia Vera
Intervention:
Sponsor: Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010
Familial Myeloproliferative Disorders

Conditions: Polycythemia Vera; Essential Thrombocythemia; Idiopathic Myelofibrosis
Intervention:
Sponsor: Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010
Correlative Biomarker Study in Patients With Myeloproliferative Disorders

Conditions: Myeloproliferative Disease; Myelofibrosis; Idiopathic Myelofibrosis; Essential Thrombocythemia; Polycythemia Vera
Intervention:
Sponsor: Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010
Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major

Conditions: Beta Thalassemia Major; Congenital Anemias
Intervention: Genetic: GCSF, Central venous line placement, Stem cell Collection (leukapheresis)
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth

Condition: Macular Telangiectasia
Intervention: Drug: Ranibizumab
Sponsor: National Eye Institute (NEI)
Recruiting - verified January 2010
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

Conditions: Multiple Myeloma; Primary Amyloidosis
Interventions: Drug: Melphalan; Procedure: Stem Cell Infusion; Behavioral: Questionnaires; Drug: Granulocyte-colony stimulating factor (G-CSF); Procedure: Apheresis
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib

Condition: Chronic Myelogenous Leukemia - Chronic Phase
Intervention: Drug: Nilotinib
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure

Condition: Hypertension
Interventions: Drug: Carvedilol CR; Drug: Atenolol
Sponsors: University of Florida; GlaxoSmithKline
Recruiting - verified February 2010
Anemia in the Elderly

Condition: Anemia
Intervention:
Sponsors: Stanford University; National Institute on Aging (NIA)
Recruiting - verified February 2010
Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition
Interventions: Biological: alemtuzumab; Drug: busulfan; Drug: fludarabine phosphate; Drug: tacrolimus; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsor: Baylor College of Medicine
Recruiting - verified June 2009
A Study of R7112 in Patients With Hematologic Neoplasms.

Condition: Hematologic Neoplasms
Intervention: Drug: RG7112
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment. (SPINART)

Condition: Hemophilia A
Interventions: Drug: Recombinant Anti-hemophilic Factor VIII (Kogenate®FS); Drug: Recombinant Anti-hemophilic Factor VIII (Kogenate®FS)
Sponsor: Bayer
Recruiting - verified March 2010
Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Conditions: MDS; Myelodysplastic Syndromes; Thrombocytopenia
Interventions: Drug: Placebo; Biological: Romiplostim
Sponsor: Amgen
Recruiting - verified March 2010
Stem Cell Transplantation To Treat High Risk Lymphoid Diseases With Reduced Toxicity Myeloablative Conditioning Regimen

Conditions: Multiple Myeloma; Plasma Cell Leukemia; Lymphoma; Chronic Lymphocytic Leukemia
Interventions: Drug: Fludarabine/Busulfan x 4 days; Procedure: stem cell transplant
Sponsors: University of Michigan Cancer Center; PDL BioPharma, Inc.
Recruiting - verified March 2010
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: lenalidomide; Drug: melphalan; Drug: prednisone; Drug: thalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

Condition: Hematologic Neoplasms
Intervention: Drug: SNX-5422
Sponsors: Pfizer; Serenex, Inc.
Recruiting - verified March 2010
Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood

Conditions: Dyslipidemias; Carotid Artery Disease; Coronary Heart Disease
Interventions: Drug: ABT-335; Drug: Placebo
Sponsor: Abbott
Recruiting - verified January 2010
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma

Conditions: Myeloproliferative Disorder; Urothelial Carcinoma; Cancer
Intervention: Drug: Bevacizumab, Carboplatin, Gemcitabine
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy

Conditions: Cancer; Leukemia; Myelodysplastic Syndrome; Non-Hodgkin's Lymphoma
Interventions: Drug: Fludarabine, Cyclophosphamide; Procedure: Transplantation
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2010
Intraoperative Optical Imaging of Brain Function

Condition: Brain Tumor
Intervention: Procedure: Speckle-Contrast Imaging
Sponsors: M.D. Anderson Cancer Center; National Institutes of Health (NIH); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2010
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Infection; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Secondary Myelofibrosis; Small Intestine Cancer
Interventions: Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: etoposide; Drug: fludarabine phosphate; Drug: melphalan; Drug: methotrexate; Drug: sirolimus; Drug: tacrolimus; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: hematopoietic stem cell transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
A Combination of Imatinib Mesylate and Pegylated Interferon α2a in Chronic-Phase Chronic Myeloid Leukemia

Condition: Chronic Myeloid Leukemia
Intervention: Drug: PEG-IFN-a2a
Sponsor: University of Michigan Cancer Center
Recruiting - verified February 2010
Photopheresis for the Treatment of Acute Graft Versus Host Disease

Condition: Graft Versus Host Disease
Interventions: Procedure: Photopheresis; Drug: Methylprednisolone
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis

Condition: Myelofibrosis
Intervention: Drug: Fludarabine, Melphalan +/- ATG
Sponsor: Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010
Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Dasatinib; Drug: Bortezomib; Drug: Dexamethasone
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Dasatinib in Combination With Revlimid (and Dexamethasone)

Condition: Multiple Myeloma
Intervention: Drug: Dasatinib + Lenalidomide + Dexamethasone
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Modifying Dietary Behavior in Adolescents With Elevated Blood Pressure

Conditions: Hypertension; Pre-Hypertension
Interventions: Behavioral: DASH-4-Teens; Other: Routine Care
Sponsor: University of Cincinnati
Recruiting - verified March 2010
Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients

Condition: Von Willebrand Disease
Intervention: Biological: Alphanate SD/HT
Sponsor: Grifols Biologicals Inc.
Recruiting - verified March 2010
An Investigational Drug, PD 0332991, Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

Condition: Multiple Myeloma
Interventions: Drug: Bortezomib; Drug: Dexamethasone; Drug: PD 0332991
Sponsor: Pfizer
Recruiting - verified March 2010
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

Conditions: Childhood Germ Cell Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Neuroblastoma; Testicular Germ Cell Tumor; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: busulfan; Drug: carboplatin; Drug: carmustine; Drug: cyclophosphamide; Drug: etoposide; Drug: melphalan; Drug: thiotepa; Radiation: total-body irradiation
Sponsors: Roswell Park Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)

Conditions: Leukemia; Myelodysplastic Syndrome
Intervention: Behavioral: Interview
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Chemotherapy, Donor Stem Cell Transplant, and Graft-Versus-Host Disease Prevention in Treating Patients With Advanced Hematologic Cancer or Other Disease

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: alemtuzumab; Biological: rituximab; Drug: cyclophosphamide; Drug: cyclosporine; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: fludarabine phosphate; Drug: methotrexate; Drug: prednisone; Drug: sirolimus; Drug: tacrolimus; Drug: vincristine sulfate
Sponsor: National Cancer Institute (NCI)
Recruiting - verified July 2009
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Adult Double Cord Blood Transplant Study

Conditions: Cord Blood Stem Cell Transplantation; Hematologic Malignancies
Intervention: Procedure: Cord blood transplantation
Sponsor: Center for International Blood and Marrow Transplant Research
Recruiting - verified March 2010
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: busulfan; Drug: cyclophosphamide; Drug: cyclosporine; Drug: etoposide; Drug: methotrexate; Drug: rasburicase; Drug: sirolimus; Drug: tacrolimus; Other: flow cytometry; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsor: Massachusetts General Hospital
Recruiting - verified April 2008
Aflibercept in Treating Patients With Myelodysplastic Syndromes

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: aflibercept; Genetic: gene expression analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Other: immunoenzyme technique; Other: immunologic technique; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified June 2009
Randomized Phase 3b Study in Previously Untreated Multiple Myeloma Patients: VELCADE,Thalidomide, and Dexamethasone Versus VELCADE and Dexamethasone Versus VELCADE, Melphalan, and Prednisone

Condition: Multiple Myeloma
Interventions: Drug: bortezomib, thalidomide, and dexamethasone (VTD); Drug: bortezomib and dexamethasone (VD); Drug: bortezomib, melphalan and prednisone (VMP)
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Condition: Chronic Idiopathic Thrombocytopenic Purpura
Interventions: Biological: Gammaplex, intravenous immunoglobulin; Biological: Gammaplex; Biological: Gammaplex
Sponsor: Bio Products Laboratory
Recruiting - verified March 2010
Fatigue and Symptom Burden in Febrile Neutropenia

Conditions: Solid Tumors; Febrile Neutropenia
Intervention: Behavioral: Questionnaire
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified February 2010
DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study

Condition: Bone Cancer
Intervention: Drug: Dalteparin
Sponsors: M.D. Anderson Cancer Center; Pfizer
Recruiting - verified March 2010
Pulmonary Hypertension, Hypoxia and Sickle Cell Disease

Conditions: Chuvash Polycythemia; Cerebrovascular Disease; Pulmonary Hypertension; Sickle Cell Anemia
Intervention:
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2010
Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes

Conditions: Myelodysplastic Syndromes; MDS
Intervention: Drug: Gimatecan
Sponsors: M.D. Anderson Cancer Center; Novartis
Recruiting - verified March 2010
Beclomethasone in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: beclomethasone dipropionate; Drug: methotrexate; Drug: tacrolimus; Other: placebo
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim; Drug: dexamethasone; Drug: melphalan; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified February 2010
Long-Term Follow Up Study for AMD3100 Patients

Condition: Myeloma
Intervention: Other: Telephone Questionnaire
Sponsors: M.D. Anderson Cancer Center; AnorMED
Recruiting - verified March 2010
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Conditions: Myelodysplastic Syndrome; Leukemia; Acute Myeloid Leukemia
Interventions: Drug: Busulfan; Drug: Fludarabine
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Chronic Myeloid Leukemia
Interventions: Drug: Clofarabine; Drug: Busulfan; Drug: Fludarabine
Sponsors: M.D. Anderson Cancer Center; Genzyme
Recruiting - verified March 2010
Hemodynamic Changes After Aortic Aneurysm Treatment With Stent-Graft

Condition: Abdominal Aortic Aneurysm
Intervention:
Sponsor: University of California, San Francisco
Recruiting - verified January 2008
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox

Condition: Anemia
Intervention: Drug: Deferasirox
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin; Biological: filgrastim; Biological: graft-versus-tumor induction therapy; Biological: therapeutic allogeneic lymphocytes; Drug: busulfan; Drug: fludarabine phosphate; Drug: melphalan; Drug: methotrexate; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: allogeneic bone marrow transplantation; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified June 2009
Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin; Biological: sargramostim; Biological: therapeutic allogeneic lymphocytes; Drug: busulfan; Drug: fludarabine phosphate; Drug: methotrexate; Drug: tacrolimus; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2008
Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: alemtuzumab; Biological: therapeutic allogeneic lymphocytes; Drug: busulfan; Drug: fludarabine phosphate; Drug: tacrolimus; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2008
Cyclophosphamide and Busulfan Followed By Donor Stem Cell Transplant in Treating Patients With Myelofibrosis

Conditions: Chronic Myeloproliferative Disorders; Secondary Myelofibrosis
Interventions: Drug: busulfan; Drug: cyclophosphamide; Drug: methotrexate; Drug: tacrolimus; Other: pharmacological study; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Myelodysplastic Syndromes; Secondary Myelofibrosis
Interventions: Biological: filgrastim; Procedure: allogeneic bone marrow transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: The Canadian Blood and Marrow Transplant Group; National Cancer Institute (NCI)
Recruiting - verified July 2009
VEGF Trap in Treating Patients With Stage II or Stage III Multiple Myeloma That Has Relapsed or Not Responded to Previous Treatment

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: aflibercept; Other: flow cytometry; Other: immunoenzyme technique; Other: immunologic technique; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Weill Medical College of Cornell University; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease

Conditions: Anemia; Chronic Kidney Disease; Kidney Disease
Interventions: Drug: darbepoetin alfa QW; Drug: darbepoetin alfa Q2W
Sponsor: Amgen
Recruiting - verified March 2010
Cellular Therapy With Cord Blood Cells

Conditions: Multiple Myeloma; Leukemia; Lymphoma
Interventions: Drug: Fludarabine; Drug: Melphalan; Procedure: Umbilical Cord Blood; Drug: Rituximab; Other: Peripheral Blood Stem Cell Infusion
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Precancerous Condition; Secondary Myelofibrosis; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: pemetrexed disodium; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsor: Robert H. Lurie Cancer Center
Recruiting - verified July 2009
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Secondary Myelofibrosis; Small Intestine Cancer
Interventions: Biological: therapeutic allogeneic lymphocytes; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: tacrolimus; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: in vitro-treated peripheral blood stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2009
Fludarabine and Total-Body Irradiation Followed By a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Secondary Myelofibrosis
Interventions: Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

Condition: Myelodysplastic Syndromes
Interventions: Drug: decitabine; Drug: tretinoin; Genetic: DNA methylation analysis; Genetic: cytogenetic analysis; Genetic: microarray analysis; Other: flow cytometry; Other: immunohistochemistry staining method
Sponsors: Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2010
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: asparaginase; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: thioguanine
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy

Condition: Breast Cancer
Intervention: Drug: chemotherapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

Conditions: Heart Failure; Anemia; Cardiovascular Disease; Ventricular Dysfunction; Congestive Heart Failure
Interventions: Drug: Darbepoetin alfa; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: cytarabine; Drug: etoposide; Drug: vorinostat; Genetic: microarray analysis; Genetic: protein expression analysis; Other: pharmacological study
Sponsors: University of Maryland Greenebaum Cancer Center; National Cancer Institute (NCI)
Recruiting - verified June 2009
PXD101 and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: azacitidine; Drug: belinostat
Sponsors: University of Chicago; National Cancer Institute (NCI)
Recruiting - verified April 2009
EXTEND (Eltrombopag Extended Dosing Study)

Condition: Idiopathic Thrombocytopenic Purpura
Intervention: Drug: eltrombopag olamine (SB-497115-GR)
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: BB-10901
Sponsor: ImmunoGen, Inc.
Recruiting - verified March 2010
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By Umbilical Cord Blood Stem Cell Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer and Other Diseases

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified December 2009
Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Biological: filgrastim; Biological: rituximab; Drug: carboplatin; Drug: carmustine; Drug: cyclophosphamide; Drug: etoposide; Drug: ifosfamide; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy; Radiation: total-body irradiation
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified July 2009
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Infection; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Intervention: Drug: moxifloxacin hydrochloride
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified July 2009
Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A

Condition: Severe Hemophilia A
Intervention: Drug: Alphanate SD/HT
Sponsor: Grifols Biologicals Inc.
Recruiting - verified March 2010
Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Osteoporosis; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: calcium citrate; Dietary Supplement: calcium glucarate; Dietary Supplement: cholecalciferol; Drug: calcium gluconate; Drug: zoledronic acid
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified October 2008
Safety, Pharmacokinetics and Efficacy of an AT-III Concentrate.

Condition: Antithrombin III Deficiency
Intervention: Drug: Plasma-derived AT-III concentrate
Sponsor: Grifols Biologicals Inc.
Recruiting - verified March 2010
Azacitidine With or Without MS-275 in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Drug: entinostat
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified October 2008
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant

Conditions: Kidney Cancer; Leukemia; Lymphoma; Myelodysplastic Syndromes; Neuroblastoma; Pulmonary Complications; Sarcoma
Interventions: Biological: etanercept; Drug: methylprednisolone
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy and Radiation Therapy Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: CD4+CD25+ regulatory T cells; Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified September 2009
Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease

Condition: Iron Overload
Intervention: Drug: deferiprone
Sponsors: Children's Hospital of Philadelphia; ApoPharma
Available - verified February 2010
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: clofarabine; Drug: cyclophosphamide
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Unusual Cancers of Childhood
Interventions: Biological: anti-thymocyte globulin; Biological: filgrastim; Biological: therapeutic allogeneic lymphocytes; Drug: busulfan; Drug: carmustine; Drug: cyclophosphamide; Drug: cyclosporine; Drug: cytarabine; Drug: etoposide; Drug: fludarabine phosphate; Drug: melphalan; Drug: methotrexate; Drug: methylprednisolone; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: peripheral blood stem cell transplantation; Procedure: umbilical cord blood transplantation; Radiation: radiation therapy
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified June 2007
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: graft-versus-tumor induction therapy; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: umbilical cord blood transplantation; Radiation: radiation therapy
Sponsor: James P. Wilmot Cancer Center
Recruiting - verified June 2007
Study of Dasatinib in Patients With Chronic Myelogenous Leukemia

Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Dasatinib (BMS-354825)
Sponsors: M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified March 2010
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition
Interventions: Biological: therapeutic allogeneic lymphocytes; Drug: busulfan; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified January 2009
Melphalan and Mannitol in Treating Patients With Central Nervous System Cancer

Conditions: Brain and Central Nervous System Tumors; Chordoma; Lymphoma; Metastatic Cancer; Von Hippel-Lindau Syndrome
Interventions: Drug: mannitol; Drug: melphalan
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Autologous Transplant for Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Procedure: Stem Cell Transplant; Drug: cyclophosphamide, melphalan; Drug: Thalidomide and Dexamethasone
Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2010
Stem Cell Transplant for Hematological Malignancy

Conditions: Leukemia, Myeloid, Chronic; AML; Leukemia, Lymphocytic, Acute; MDS; Leukemia, Lymphocytic, Chronic; JMML; Hodgkin's Disease; Non-Hodgkin's Lymphoma; Multiple Myeloma
Interventions: Procedure: Stem Cell Transplant; Drug: Cyclophosphamide; Radiation: Total Body Irradiation; Drug: Busulfan
Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2010
Stem Cell Transplant for Immunologic or Histiocytic Disorders

Conditions: Hemophagocytic Lymphohistiocytosis; X-Linked Lymphoproliferative Disorders; Chediak-Higashi Syndrome; Griscelli Syndrome; Immunologic Deficiency Syndromes; Langerhans-Cell Histiocytosis
Interventions: Procedure: Stem Cell Transplant; Drug: Fludarabine, melphalan, ATG or Campath
Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2010
Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn

Condition: Burns
Intervention: Drug: Recombinant Factor VIIa
Sponsor: United States Army Institute of Surgical Research
Recruiting - verified February 2010
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: allogeneic bone marrow transplantation; Radiation: radiation therapy
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy, Tacrolimus, and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant For Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Drug: busulfan; Drug: cyclophosphamide; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: allogeneic bone marrow transplantation; Procedure: bone marrow ablation with stem cell support
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Hypertension Intervention Nurse Telemedicine Study (HINTS)

Condition: Hypertension
Interventions: Behavioral: Nurse Behavioral intervention with Home BP Telemonitoring; Behavioral: Nurse Medication Management with Home BP Telemonitoring; Behavioral: Nurse Combined intervention with Home BP Telemonitoring
Sponsor: Department of Veterans Affairs
Recruiting - verified March 2010
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

Condition: Leukemia, Myelogenous, Chronic
Intervention: Drug: Nilotinib
Sponsors: M.D. Anderson Cancer Center; Novartis
Recruiting - verified March 2010
Alemtuzumab, Fludarabine, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: alemtuzumab; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm
Intervention: Drug: fenretinide
Sponsors: California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified July 2009
Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes

Conditions: Hemoglobinopathies; Hemolysis; Iron Deficiency and Overload; Anemias
Intervention:
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2010
Pentostatin and Donor White Blood Cells in Preventing Graft Rejection in Cancer Patients Who Have Undergone Donor Stem Cell Transplantation

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Sarcoma; Testicular Germ Cell Tumor
Interventions: Biological: therapeutic allogeneic lymphocytes; Drug: cyclosporine; Drug: mycophenolate mofetil; Drug: pentostatin
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Decitabine in Treating Patients With Myelofibrosis

Condition: Chronic Myeloproliferative Disorders
Intervention: Drug: decitabine
Sponsors: University of Chicago; National Cancer Institute (NCI)
Recruiting - verified June 2007
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: graft-versus-tumor induction therapy; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified December 2009
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: filgrastim; Biological: graft-versus-tumor induction therapy; Biological: rituximab; Biological: therapeutic allogeneic lymphocytes; Drug: cyclophosphamide; Drug: cyclosporine; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: fludarabine phosphate; Drug: prednisone; Drug: vincristine sulfate; Procedure: peripheral blood stem cell transplantation
Sponsor: National Cancer Institute (NCI)
Recruiting - verified July 2009
Sirolimus in Preventing Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: therapeutic allogeneic lymphocytes; Drug: sirolimus
Sponsor: National Cancer Institute (NCI)
Recruiting - verified November 2007
Rituximab, Carboplatin, Cyclophosphamide, and Etoposide or Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Sodium Thiosulfate and Cytarabine in Treating Patients With Refractory or Recurrent Primary CNS Lymphoma

Conditions: Brain and Central Nervous System Tumors; Drug/Agent Toxicity by Tissue/Organ; Lymphoma; Thrombocytopenia
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Biological: rituximab; Drug: blood-brain barrier disruption chemotherapy; Drug: carboplatin; Drug: cyclophosphamide; Drug: cytarabine; Drug: etoposide; Drug: etoposide phosphate; Drug: sodium thiosulfate
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members

Conditions: Neoplasms; Hematologic Neoplasms
Intervention:
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2010
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Allogeneic Transplantation

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Sarcoma; Testicular Germ Cell Tumor
Intervention: Biological: therapeutic allogeneic lymphocytes
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified December 2009
Randomized Double Cord Blood Transplant Study

Conditions: Leukemia, Lymphocytic, Acute; Leukemia, Myelocytic, Acute; Leukemia, Myeloid, Chronic; Lymphoma, Non-Hodgkin
Interventions: Procedure: Expanded allogeneic cord blood (CB); Procedure: One Unmanipulated and One Expanded Cord Blood Unit
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: dexamethasone; Drug: melphalan; Drug: thalidomide; Procedure: peripheral blood stem cell transplantation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Technical Development of Cardiovascular Magnetic Resonance Imaging

Condition: Peripheral Artery Disease
Intervention: Procedure: MRI
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2010
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: anti-thymocyte globulin; Biological: filgrastim; Drug: cyclophosphamide; Drug: fludarabine phosphate; Procedure: umbilical cord blood transplantation; Drug: methylprednisolone
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Aplastic Anemia

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: anti-thymocyte globulin; Biological: graft-versus-tumor induction therapy; Biological: sargramostim; Biological: therapeutic allogeneic lymphocytes; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: methylprednisolone; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: allogeneic bone marrow transplantation; Procedure: peripheral blood stem cell transplantation; Procedure: umbilical cord blood transplantation
Sponsors: Roswell Park Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Screening Individuals and Families at High Risk for Hematologic Cancers

Conditions: Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Genetic: genetic linkage analysis; Genetic: microarray analysis; Other: counseling intervention; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: evaluation of cancer risk factors
Sponsor: National Cancer Institute (NCI)
Recruiting - verified April 2007
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With T(15;17)(q22;q12); Adult Acute Myeloid Leukemia With T(16;16)(p13;q22); Adult Acute Myeloid Leukemia With T(8;21)(q22;q22); B-cell Adult Acute Lymphoblastic Leukemia; B-cell Childhood Acute Lymphoblastic Leukemia; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; T-cell Adult Acute Lymphoblastic Leukemia; T-cell Childhood Acute Lymphoblastic Leukemia
Interventions: Biological: therapeutic allogeneic lymphocytes; Biological: aldesleukin; Procedure: peripheral blood stem cell transplantation; Procedure: allogeneic bone marrow transplantation; Other: laboratory biomarker analysis; Genetic: gene expression analysis; Other: immunologic technique; Other: flow cytometry; Genetic: polymerase chain reaction; Genetic: cytogenetic analysis; Other: staining method
Sponsor: Fred Hutchinson Cancer Research Center
Recruiting - verified March 2010
Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma

Conditions: Leukemia; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Genetic: chromosomal translocation analysis; Genetic: cytogenetic analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation

Conditions: Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Oral Complications; Ovarian Cancer; Pain; Sarcoma
Interventions: Procedure: management of therapy complications; Procedure: pain therapy
Sponsor: Medical College of Wisconsin
Recruiting - verified June 2009
Assessment of Blood Vessel Density in Kaposi's Sarcoma Lesions

Condition: Kaposi's Sarcoma
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting - verified August 2009
Collection and Storage of Umbilical Cord Stem Cells for Treatment of Sickle Cell Disease

Conditions: Healthy; Sickle Cell Anemia
Intervention:
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2009
Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer

Conditions: HIV Infection; Kaposi's Sarcoma
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting - verified April 2009
Blood Factors and Diabetic Retinopathy

Condition: Diabetic Retinopathy
Intervention:
Sponsor: National Eye Institute (NEI)
Recruiting - verified September 2009
Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection

Condition: Hepatitis C
Intervention:
Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting - verified February 2010
A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure

Conditions: Aplastic Anemia; Pure Red Cell Aplasia; Diamond Blackfan Anemia
Interventions: Drug: Daclizumab; Drug: Daclizumab (Zenapax)
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified September 2009
Chemotherapy and Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Disease or Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: anti-thymocyte globulin; Biological: therapeutic allogeneic lymphocytes; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Procedure: peripheral blood stem cell transplantation
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2009
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

Conditions: Graft vs Host Disease; Healthy; Lymphopenia
Intervention: Drug: G-CSF
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 2009
Evaluation and Follow-up of Patients With Cryptococcosis

Conditions: Cryptococcosis; Lymphopenia
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2009
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonmalignant Neoplasm; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: anti-thymocyte globulin; Drug: busulfan; Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: fludarabine phosphate; Drug: melphalan; Drug: thiotepa; Radiation: total-body irradiation
Sponsor: Roswell Park Cancer Institute
Recruiting - verified June 2009

Paid Clinical Trials for Blood Disorders, Abetalipoproteinemia - Clinical Trials

Paid Clinical Trials for Blood Disorders, Abetalipoproteinemia

Paid Clinical Trials and Focus Groups by Category

Main Menu

Find Clinical Trials

Clinical Trial Locations

Clinical Trial Categories

Patient Recruiting...

Paid Clinical Trials